 Englewood Cliffs NJ, Oct. 07, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTCQB: SILO a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. 